Sandra Poole

CIK 1619622 · Chief Operating Officer · last filed 2026-05-21

Sandra Poole is a Chief Operating Officer who has filed 13 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for TVTX, was dated May 21, 2026. Current disclosed insider exposure totals $2.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$2.23M

Companies

4

Total Filings

13

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
TVTX	Director	34,000	$65.71	$2.23M	$0	6	2026-05-21
Travere Therapeutics, Inc. (RTRX) Delisted	Director	6,500	—	—	$0	2	2020-05-19
LogicBio Therapeutics, Inc. (LOGC) Delisted	Chief Operating Officer	—	$7.06	—	$0	2	2018-10-24
ImmunoGen, Inc. (IMGN) Delisted	Executive VP, Tech Operations	—	$31.23	—	$0	3	2016-10-20

Recent Filings

13 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-05-21	TVTX	Grant (A)	+4,000	$0	EDGAR
2025-05-16	TVTX	Grant (A)	+6,500	$0	EDGAR
2024-05-10	TVTX	Grant (A)	+6,500	$0	EDGAR
2023-05-19	TVTX	Grant (A)	+4,500	$0	EDGAR
2022-05-12	TVTX	Grant (A)	+3,000	$0	EDGAR
2021-05-18	TVTX	Grant (A)	+3,000	$0	EDGAR
2020-05-19	Travere Therapeutics, Inc. (RTRX) Delisted	Grant (A)	+3,000	$0	EDGAR
2019-05-15	Travere Therapeutics, Inc. (RTRX) Delisted	Grant (A)	+3,500	$0	EDGAR
2018-10-24	LogicBio Therapeutics, Inc. (LOGC) Delisted	Grant (A)	—	$0	EDGAR
2018-10-22	LogicBio Therapeutics, Inc. (LOGC) Delisted	Grant (A)	—	$0	EDGAR

Showing 1–10 of 13

Page 1 of 2 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.